Skip to main content
Download PDF

Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer’s disease

BMC Medicine volume 21, Article number: 223 (2023) Cite this article

Abstract

Background

The identification of pathogenic mutations in Alzheimer’s disease (AD) causal genes led to a better understanding of the pathobiology of AD. Familial Alzheimer’s disease (FAD) is known to be associated with mutations in the APP, PSEN1, and PSEN2 genes involved in Aβ production; however, these genetic defects occur in only about 10–20% of FAD cases, and more genes and new mechanism causing FAD remain largely obscure.

Methods

We performed exome sequencing on family members with a FAD pedigree and identified gene variant ZDHHC21 p.T209S. A ZDHHC21T209S/T209S knock-in mouse model was then generated using CRISPR/Cas9. The Morris water navigation task was then used to examine spatial learning and memory. The involvement of aberrant palmitoylation of FYN tyrosine kinase and APP in AD pathology was evaluated using biochemical methods and immunostaining. Aβ and tau pathophysiology was evaluated using ELISA, biochemical methods, and immunostaining. Field recordings of synaptic long-term potentiation were obtained to examine synaptic plasticity. The density of synapses and dendritic branches was quantified using electron microscopy and Golgi staining.

Results

We identified a variant (c.999A > T, p.T209S) of ZDHHC21 gene in a Han Chinese family. The proband presented marked cognitive impairment at 55 years of age (Mini-Mental State Examination score = 5, Clinical Dementia Rating = 3). Considerable Aβ retention was observed in the bilateral frontal, parietal, and lateral temporal cortices. The novel heterozygous missense mutation (p.T209S) was detected in all family members with AD and was not present in those unaffected, indicating cosegregation. ZDHHC21T209S/T209S mice exhibited cognitive impairment and synaptic dysfunction, suggesting the strong pathogenicity of the mutation. The ZDHHC21 p.T209S mutation significantly enhanced FYN palmitoylation, causing overactivation of NMDAR2B, inducing increased neuronal sensitivity to excitotoxicity leading to further synaptic dysfunction and neuronal loss. The palmitoylation of APP was also increased in ZDHHC21T209S/T209S mice, possibly contributing to Aβ production. Palmitoyltransferase inhibitors reversed synaptic function impairment.

Conclusions

ZDHHC21 p.T209S is a novel, candidate causal gene mutation in a Chinese FAD pedigree. Our discoveries strongly suggest that aberrant protein palmitoylation mediated by ZDHHC21 mutations is a new pathogenic mechanism of AD, warranting further investigations for the development of therapeutic interventions.

Peer Review reports

Background

Alzheimer’s disease (AD) is a devastating neurodegenerative disease that afflicts a large portion of the older population at an ever-increasing rate. Synaptic dysfunction, neuronal loss, amyloid plaques, neurofibrillary tangles, brain atrophy, and cognitive impairment are the pathological and clinical features of AD [1,2,3,4]. Mutations in genes involved in amyloid beta (Aβ) production, such as Aβ precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2), are known to play major roles in certain cases of familial AD (FAD) [5,6,7,8]. The identification of causal gene mutations has greatly improved our understanding of the genetic mechanisms underlying AD. However, most of these pathogenic mutations display an autosomal-dominant pattern of inheritance and occur in a low proportion (< 5%) of patients with AD [9, 10]. Recently, the Chinese Familial Alzheimer’s Disease Network (CFAN) was established to study the genetic features of Chinese individuals with FAD [11]. In total, 1330 patients with AD or mild cognitive impairment in 404 pedigrees were enrolled; among them, 13.12% of pedigrees carried PSEN/APP missense mutations, 3.71% carried PSEN/APP synonymous/untranslated region variants, and 83.17% did not carry such mutations or variants [11]. This low mutation rate suggests that other genes and mechanism may be involved in FAD.

In addition to causal variants, variants in more than 600 genes have been investigated as susceptibility factors for AD, including APOE, TREM2, SORL1, and ABCA7. The diversity of cellular functions implicated by the growing list of risk variants associated with AD underscores the pathogenic heterogeneity of the disease. All such results add to the knowledge of the pathogenic mechanisms that drive the development of AD. However, to date, results of clinical trials in AD have been disappointing. Thus, more causal and/or risk-related gene variants and new mechanisms need to be uncovered to improve the understanding of the complex pathogenesis of AD.

In this study, we identified a rare gain-of-function variant, p.T209S, in the zinc finger DHHC-type palmitoyltransferase 21 (ZDHHC21) gene on chromosome 9 that segregated with the disease in an autosomal-dominant pattern in a Chinese family with FAD. We constructed ZDHHC21 p.T209S mice by using the CRISPR/Cas9 system to characterize the pathogenesis related to this variant. We discovered that ZDHHC21 p.T209S contributed to AD by enhancing the palmitoylation of FYN and APP, resulting in AD pathology and synaptic dysfunction, ultimately causing cognitive impairment. Furthermore, we revealed that palmitoylation inhibitors rescued the impaired synaptic function. Our results indicate that palmitoylation modification of specific substrates is an alternative driving mechanism of AD and suggest that palmitoylation is a promising target for drug therapy.

Methods

Antibodies

The following antibodies were used in this study: anti-Fyn (catalogue no. ab1881, Abcam), anti-Fyn (catalog no.: sc-434, Santa Cruz Biotechnology), anti-APP (catalog no.: ab32136, Abcam), anti-actin (catalog no.: TA-09, Zsgb-Bio, China), anti-NMDAR2B (catalog no.: ab254356, Abcam), anti-ZDHHC21 (catalog no.: PA5-25,096, Invitrogen, USA), anti-NeuN (catalog no.: ab279295, Abcam), anti-tau (phospho T231; catalog no.: ab151559, Abcam), anti-tau (phospho Thr181; catalog no.: 701530, Invitrogen), anti-Aβ (catalog no.: ab201060, Abcam), anti-phospho-Src family (catalog no.: 2101S, Cell Signaling Technology, USA), horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG heavy chain-specific secondary antibody (catalog no.: A25222, Abbkine, China), HRP-conjugated mouse anti-rabbit IgG light chain (catalog no.: A25022, Abbkine), goat anti-mouse IgG H&L (HRP; catalog no.: ab6789, Abcam), goat anti-rabbit IgG H&L (HRP; catalog no.: ab205718, Abcam), goat anti-rabbit IgG H&L (Cy3; catalog no.: ab6939, Abcam), and goat anti-mouse IgG H&L (FITC; catalog no.: ab6785, Abcam).

Patients and ethical considerations

We recruited patients with a positive family history from the CFAN [11]. In two generations of this family, three family members (I-2, II-2, and II-6) had AD, and II-6 was the proband. She was evaluated using the MMSE, the CDR scale, CT, and molecular neuroimaging with PET. The MMSE is used as the gold standard for cognitive deficit screening, with a total score ranging from 0 to 30, with lower scores reflecting worse impairment. The global CDR score ranges from 0 (healthy) to 3 (severe dementia) [12]. N-methyl-[11C]2-(4’-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) positron emission tomography (PET) was used to measure Aβ retention. [13]. The diagnostic criteria for AD were mainly based on recommendations of the National Institute on Aging and Alzheimer's Disease [14]. The institutional review board of Xuanwu Hospital, Capital Medical University, approved this study, and all participants provided written informed consent.

Gene sequencing and cosegregation analysis

Whole exome sequencing was performed on the patients to identify pathogenic genes. Briefly, genomic DNA was extracted from peripheral blood and fragmented into 200–300-bp fragments. DNA libraries were prepared using a KAPA Library Preparation Kit (catalog no.: KR0453, Kapa Biosystems, USA). The amplified DNA sample was captured using the Agilent SureSelectXT2 Human All Exon V6 kit (Agilent Technologies, USA), and sequenced on the Illumina NovaSeq S4 platform (Illumina, USA) with 150-bp paired-end reads, according to the standard manual. Raw data were filtered and aligned against the human reference genome (UCSC hg19) by using the Burrows-Wheeler Alignment tool (BWA-0.7.12, http://bio-bwa.sourceforge.net/). GATK software (www.broadinstitute.org/gatk) was used to call single-nucleotide polymorphisms, insertions, and deletions. The Ensembl Variant Effect Predictor was used to annotate all variants for position, type, allele frequency, conservation prediction, etc. [15]. We used the HGMD (https://www.hgmd.cf.ac.uk/) to confirm previously reported pathogenic mutations. Multiple software programs, such as SIFT, PolyPhen-2, and Mutation Taster, were used to predict the impact of the variants. All candidate pathogenic variants were confirmed via Sanger sequencing and classified according to the American College of Medical Genetics and Genomics standards. Cosegregation analysis was performed in light of previous methods [16].

Generation of ZDHHC21 p.T209S mutant mouse model

Mice with c.999A > T point mutations in Zdhhc21 were designed and generated by Shanghai Model Organisms Center, Inc. (China). Briefly, Cas9 mRNA was transcribed in vitro using the mMESSAGE mMACHINE T7 Ultra Kit (catalog no.: AM1344, Ambion, USA), according to the manufacturer’s instructions, and subsequently purified using the MEGAclear™ Kit (catalog no.: AM1908, Thermo Fisher Scientific, USA). 5'-TCAAAGGTAGTCAAACAGTATGG-3' was chosen as the Cas9 targeted single guide RNA (sgRNA), transcribed in vitro using the MEGAshortscript Kit (catalog no.: AM1345, Thermo Fisher Scientific), and subsequently purified using a MEGAclear™ Kit. The transcribed Cas9 mRNA and sgRNA, as well as 224 bp of single-stranded oligodeoxynucleotides (ssODNs), were co-injected into zygotes of C57BL/6 J mice. The F0 mice were validated via PCR and sequencing with the following primer pairs: F1: 5’-ACACTCTGAAGACTGTTGTTGGAAGC-3’ and R1: 5’GCACTGTAGATATGAAGGGGTTGC-3’. F0 mice with the expected point mutations were chosen and crossed with C57BL/6 J mice to produce F1 mice. The genotypes of the F1 mice were identified via PCR and confirmed via sequencing. The sequence of the ssODN for the mice with point mutations was as follows:

5'-AACTTGTTAAAAGTATTTATAAATTTGTTACATCTGAATATAATTTTTTGTTTTTAATAGGATTCAACATCTATTGAAAAAATGTCAAATTGTTGTGAAGAAATGTAAGTATTAAGTTATAGTGATCTTATTTAAAAATAGAAACGATACTGTTTGACTACCTTTGAGAATCATGTGCCTATGTTAATAGTAGGAAACTAATATGTTGATTTTTTTTTCTTGGT-3’.

The Specific pathogen Free environment was required for the housing and husbandry conditions of mice in this study (Approval Number: Medical document No. 01–4058).

Culture of mouse primary cortical neurons

Primary neurons were obtained on embryonic days 15–16 from C57BL/6 J WT and ZDHHC21T209S/T209S pregnant mice. The meninges and vascular membranes were quickly removed, and the cerebral cortex tissues were digested with TrypLE Select Enzyme (catalog no.: 12563011, Gibco, USA) for 10 min and subsequently added to complete Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum and 0.1 mg/ml DNase I (catalog no.: 10104159001, Sigma, Germany). This solution was mechanically separated 30 times to gain a cell suspension, and the cells were cultured in poly-D-lysine-coated (catalog no.: P6407, Sigma) 6-well plates at a density of 1 × 106 cells/well in a neurobasal medium (catalog no.: 21103049, Gibco) with 2% B27 supplement (catalog no.: 17504044, Gibco) and 1% glutamine (catalog no.: 35050061, Gibco).

Morris water maze task

The Morris water maze test was performed as described in our previous experiments, with slight modification [17]. On the first day of training, the platform was located 1 cm above the water surface, and a small flag was placed on the platform to increase recognition. Subsequently, mice were trained to find a platform hidden 1 cm below the water surface for four consecutive days. The complete training process lasted five days, including four tests per day, using different entry points (up to 60 s; 30-min intervals). The probe trial was performed on day 6. We calculated the number of times each mouse crossed the platform position and the time spent in the quadrant where the platform was located. The trajectory was recorded by using the Smart 3.0 video tracking system (Panlab, Spain).

Western blotting

Western blotting was performed according to our previous protocol, with minor changes [18, 19]. Briefly, for total protein extraction, cells and tissues were lysed in RIPA lysis buffer (catalog no.: C1053, Applygen, China) with 100 W ultrasound for 3 min, in which the ultrasonic time was 10 s and the rest time was 30 s, repeated three times. The samples were subsequently centrifuged at 12,000 × g for 20 min, after which the protein supernatant was absorbed. For membrane proteins, we strictly followed the Mem-PER Plus Membrane Protein Extraction Kit (catalog no.: P0033, Beyotime, USA). First, we took approximately 100 mg of mouse brain tissue and carefully cut it into tiny fragments with scissors. Thereafter, we added 1 ml of membrane protein extraction reagent A with phenylmethylsulphonyl fluoride (1 mM), gently suspended the tissue fragments in an ice bath for 10–15 min, transferred the tissue sample to a pre-chilled glass homogenizer for approximately 30–50 rounds of homogenization, and centrifuged it at 4 °C and 700 × g for 10 min. We carefully collected the supernatant into a fresh centrifuge tube to remove nuclei and unbroken cells and centrifuged it at 4 °C and 14,000 × g for 30 min to pellet cell membrane debris. Thereafter, we added 200 μl of membrane protein extraction reagent B and vortexed the solution and incubated it in an ice bath 15 times to adequately extract membrane proteins. Finally, we centrifuged the solution at 4 °C and 14,000 × g for 5 min and collected the supernatant as the cell membrane protein solution. Protein concentration was measured via the BCA method, and we used the SDS protein-loading method for denaturation. The protein samples were loaded for SDS/PAGE.

Co-immunoprecipitation

Proteins were obtained from tissues lysed in lysis buffer (30 mM HEPES, 100 mM NaCl, 0.5% Nonidet P-40, protease inhibitor mixture, pH: 7.6) on ice for 30 min, followed by centrifugation at 13,000 rpm for 10 min. Immunoprecipitation was performed with 500 μg protein in the presence or absence of APP/FYN-specific antibodies (1:200, Abcam, UK). After incubation for 3 h, protein A/G agarose beads were added for 1 h and pulled down. The immune complexes were washed three times with phosphate-buffered saline (PBS), eluted with 2 × sample buffer, and subjected to 10% SDS-PAGE. We used 1% (relative to that used for immunoprecipitation) of the lysate as input. We analyzed the presence of relevant proteins in immune complexes via western blotting using anti-ZDHHC21 (1:200, Thermo Fisher Scientific) antibodies.

Immunofluorescent staining

We used 4-μm paraffin-embedded sections of the mouse brain for immunostaining, first permeating and dehydrating it in xylene and gradient anhydrous ethanol, followed by immune antigen repair with sodium citrate (pH: 6.0) or Tris–EDTA (pH: 9.0). Subsequently, the primary anti-ZDHHC21 (1:50, Thermo Fisher Scientific) and anti-FYN (1:20, Santa Cruz Biotechnology, USA) antibodies were cultured at 4℃ overnight, and incubated with fluorescently labeled secondary antibodies (Cy3-labeled ZDHHC21, 1:100, Abcam; fluorescein isothiocyanate [FITC]-labeled FYN, 1:100, Abcam) for 2 h at 37℃. Anti-NeuN and TUNEL co-staining was performed: 40 μl TUNEL detection solution (catalog no.: 11684817910, Roche, Switzerland) was added to the sections, the sections were incubated at 37 °C for 2 h, and the sections were incubated overnight with anti-NeuN at 4℃. Sections were incubated in saline with a mixture of Cy3-labeled second-generation antibodies (1:300, Abcam), and DAPI (catalog no.: 40728ES03, Yeasen, China) was used for nuclear staining. Brain sections were sealed with an anti-fluorescence quenching sealing solution and imaged using a laser confocal microscope (Zeiss LSM 980, Zeiss, Germany).

Immunohistochemistry

After perfusion with 0.01 M PBS and dissection, the left hemibrain of each mouse was fixed with 4% paraformaldehyde, dehydrated with ethanol and xylene, and embedded in paraffin for preservation. Brain tissues were sectioned with a paraffin microtome to a thickness of 5 μm and mounted on poly-L-lysine-coated slides. Antigen retrieval was performed using 10 mM sodium citrate (pH: 6.0) and 15 min of microwaving. After being washed with PBS, the sections were pre-treated with 3% H2O2/3% methanol in PBS for 10 min to block endogenous peroxide activity. For Aβ, the sections were blocked in PBS containing 10% normal goat serum for 30 min at 37℃, and subsequently incubated with anti-Aβ (1:2000, Abcam) for 1 h at 37℃. The sections were incubated with biotin-labeled secondary antibodies (goat anti-rabbit IgG [H&L], 1:2000, Abcam) for 30 min at room temperature, washed with PBS, and incubated with the ABC kit (catalog no.: PK-6100, Vectastain, China). For p-tau, the sections were blocked in PBS containing 3% bovine serum albumin for 30 min at 37℃, and incubated with anti-tau (phospho T231, 1:500, Abcam) for 1 h at room temperature. The sections were incubated with horseradish enzyme-labeled secondary antibodies (goat anti-rabbit IgG [H&L], 1:2000, Abcam) for 30 min at room temperature. Positive signals were visualized using a DAB kit (catalog no.: DA1010, Solarbio, China). The sections were stained with Mayer’s hematoxylin solution (catalog no.: G1080, Solarbio) for 30 s, dehydrated in ethanol and xylene, mounted with neutral gum, and imaged with a microscope (Olympus CX33, Olympus, Japan).

For Aβ and p-tau quantification, 16 bit images were converted to 8 bit gray-scale images. After defining the region of interest (hippocampal CA1 and DG), they were thresholded within a linear range using NIH ImageJ software (https://imagej.nih.gov/ij/) [20]. The images were then adjusted to the same threshold to increase the signal-to-noise ratio. Four sections per mouse were quantified. The quantification of WT and ZDHHC21T209S/T209S mice was performed in a blinded manner.

ABE palmitoylation assay

This method is based on a previously described ABE assay with slight modification [21]. Briefly, hippocampal tissues of 6-month-old mice were lysed in RIPA buffer containing protease and phosphatase inhibitors to adjust the protein concentration to 1.0 μg/µl. At least 500 μg of total protein in 500 μl lithium borate buffer was precipitated with chloroform–methanol before 10 mM N-ethylmaleimide treatment at 4℃ overnight. After three rounds of precipitation with chloroform–methanol, palmitate was cleaved from cysteines on the protein with hydroxylamine (HA), and the absence of HA cleavage served as a negative control. All proteins were nutated for 45 min at room temperature. Thereafter, 1 μM of biotin-BMCC was used to label the free thiol groups of cysteines on the proteins, with 45 min of nutation at 4 °C. The biotin-conjugated target protein was captured using streptavidin-agarose beads and eluted with SDS sample buffer containing β-mercaptoethanol. Palmitoylation of the target protein was detected via western blotting with the corresponding antibody.

ELISA

Aβ ELISA kits were used to measure Aβ42 (catalog no.: CSB-E10787m, Cusabio, China) and Aβ40 (catalog no.: CSB-E08300m, Cusabio) levels. In short, the tissues were ultrasonically lysed in PBS liquid and centrifuged at 12,000 rpm at 4 °C for 20 min. The supernatant of the lysate was transferred to a 96-well plate. It was incubated with the secondary antibody at room temperature for 1 h, and the optical density was measured at 450 nm.

Golgi staining

Golgi staining was conducted in strict accordance with the manufacturer’s information via the FD Rapid GolgiStain Kit (catalog no.: PK-401, FD NeuroTechnologies, USA). Briefly, solutions A and B were mixed 24 h in advance. The tissue was immersed in that mixture for 2 weeks, transferred to solution C for 5 days, immersed in isopentane liquid (catalog no.: M108172; Aladdin, China), mixed with dry ice for freezing, embedded with a freezing embedding agent (catalog no.: TFM-5, Sakura, USA), and frozen at − 80℃. Thereafter, the tissues were cut into sections of 100 μm for silver staining and dehydrated in gradient alcohol. The background color was removed in xylene liquid and the sections were sealed with gum (catalog no.: 36313ES60, Yeasen). The tissue sections were observed under a forward fluorescence microscope (Nikon DS-Ri2, Nikon, Japan).

For statistical analysis of dendritic spines and branches, we used Sholl analysis [22] (via the FIJI image processing package). First, we converted the image into 8 bits, set the scale, and saved it. Second, we opened the image, tracked the trajectory of the neuron, measured the length of the neuron, and performed neuron tracing with the plugin “neuron J.” Finally, we used the plugin “sholl analysis” to form concentric circles of isometric distance around the neuron. We calculated the number of intersections of dendrites and concentric circles, as such intersections indirectly reflect the length of the dendrites and the number of branches.

Transmission electron microscopy

According to a published protocol [23], after anesthesia, mice were injected into the left ventricle with 4% paraformaldehyde. Hippocampal sections were fixed in cold 1% OsO4 for 1 h. The specimens were prepared and tested according to standard procedures. Ultrathin Sects. (90 nm) were stained with uranyl acetate and lead acetate and observed under a transmission electron microscope (Tecnai G2 20 Twin, FEI, USA). Synapses were identified based on synaptic vesicles and postsynaptic density.

RNA isolation and quantitative reverse transcription-PCR analysis

RNA was extracted as previously described [18], using the Total Cell/Tissue RNA Isolation Kit (catalog no.: RC112-01, Vazyme, China), and reverse-transcribed to cDNA by using the HiScript II Q Select RT SuperMix (catalog no.: R233-01, Vazyme). Quantitative PCR (qPCR) was performed using the AceQ Universal SYBR qPCR Master Mix (catalog no.: Q511-02, Vazyme) on an Applied Biosystems instrument (Thermo Fisher Scientific, USA). The qPCR protocol was as follows: 40 cycles of 95 °C for 5 min, 95 °C for 10 s, and 60 °C for 30 s. Relative expression was calculated with the 2-ΔΔCT method [24].

The ZDHHC21 primer pairs were as follows: F: 5’-ATGGGTCTTCGGATTCACTTTG-3’, R: 5’-CCCTCACTAAGGCAACCAGG-3’.

Electrophysiology

Three-month-old male mice were anesthetized by intraperitoneal injection of pentobarbital (0.05 g/kg body weight) and decapitated. Coronal hippocampal Sects. (400 µm) were prepared using a vibrating microtome (Leica VT2000S, Leica Biosystems, Germany) in ice-cold slicing buffer aerated with 95% O2 and 5% CO2 (26 mM NaHCO3, 1.25 mM NaH2PO4, 2.5 mM KCl, 0.5 mM CaCl2, 4 mM MgCl2, 10 mM dextrose, and 206 mM sucrose). Sections were submerged in oxygenated artificial cerebrospinal fluid (ACSF; 125 mM NaCl, 26 mM NaHCO3, 1.25 mM NaH2PO4, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 10 mM dextrose) for 1 h at room temperature. Recordings were acquired using a MultiClamp 700B microelectrode amplifier and Digidata 1440A low-noise data acquisition system (Molecular Devices, USA). fEPSPs were evoked in the CA1 stratum radiatum by stimulating the Schaffer collateral with a bipolar tungsten electrode and recorded with ACSF-filled glass pipettes (resistance < 1 MΩ) at 30 °C. Baseline responses were set to 40% of the maximal response and were recorded for 15 min. Long-term potentiation was induced by one 100 Hz tetanus (1 s). The data were analyzed using Clampfit 10 software (Molecular Devices). The peak amplitude of the fEPSP was measured as an index of synaptic strength and expressed as a percentage of the baseline average.

NMDA-mediated excitotoxicity assays

We measured the impact of palmitoylation on cell viability following exposure of WT and ZDHHC21209S/T209S neurons to NMDA and glycine by plating and pretreating primary cortical neurons with dimethyl sulfoxide (vehicle), 1 µM 2-BP (catalog no.: 238422, Sigma) or 1 µM cerulenin (catalog no.: C102399, Aladdin) between DIV11 and DIV18. Subsequently, feeding medium was removed from the neurons, stored at 37℃, and replaced with B27 neurobasal medium with or without NMDA/glycine at concentrations of 100/10 µM, respectively. After incubation at 37℃ for 2 h, the treatment medium was removed and replaced with the original feeding medium. The cells were incubated for an additional 22 h. Cell viability was assayed using the PrestoBlue HS cell viability reagent (catalog no.: P50200, Thermo Fisher Scientific) and measured using a Thermo Fisher Multiskan GO Multimode Detector, according to the manufacturer’s instructions. Cell viability was calculated as a percentage of vehicle-treated control cells.

Calcium imaging analyses

For direct imaging of calcium signaling in the primary neurons of WT and ZDHHC21209S/T209S mice, a construct encoding GCaMP3 (catalog no.: Plasmid 22,692, Addgene, USA) was introduced into the cells at DIV8. One group of cells was treated with 1 µM 2-BP (catalog no.: 10005647, Cayman Chemicals, USA) between DIV12 and DIV18. Cells were cultured to DIV18 and imaging was performed for up to 15 min in Tyrode’s solution (imaging medium, 139 mM NaCl, 3 mM KCl, 17 mM NaHCO3, 12 mM glucose, and 3 mM CaCl2) by using a camera mounted on a laser confocal microscope (Zeiss LSM 980, Zeiss). Each neuron was recorded for up to 5 min (at least three neurons per coverage; n = 3–6 neurons/group, three independent experiments). When Ro 25–6981 was processed, neurons were imaged at baseline for an initial 2–2.5 min; thereafter, Ro 25–6981 (1 µM) was added directly to the imaging medium before the neurons were imaged for an additional 2.5 min. p.T209S primary neurons at DIV12-18 (every other day) underwent intervention with the palmitoylation inhibitor 2-BP (1 µM). Using the FIJI software and referring to a prior method [25], the transient calcium ion AUC and diffusion distance of neurons were analyzed.

Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics, version 26 (International Business Machines Corporation, USA). First, we analyzed whether the data were normally distribution. Data that were normally distributed were compared using parametric tests (t tests for two groups and one-way ANOVAs for multi-group comparisons). Data that were not normally distributed were analyzed using a non-parametric test (the Wilcoxon–Mann–Whitney test). P < 0.05 was considered statistically significant. Values are presented as the mean ± standard error of the mean (SEM). All measurements and analyses were performed in a blinded manner.

Results

Discovery of an FAD pedigree with a novel mutation of the ZDHHC21 gene

The proband (II-6) was a 55-year-old woman (Fig. 1A). The proband presented to our neurology department in 2015 with complaints of gradual and progressive memory decline. Five years prior to that, the patient started experiencing difficulties in remembering what she did in daily life. Two years prior, she was unable to live by herself and needed help from family members. At our memory clinic, she could not answer most of the questions asked by the doctors. Neurological examination revealed cognitive deficits. Her Mini-Mental State Examination (MMSE) score was 5, and her Clinical Dementia Rating (CDR) score was 3. N-methyl-[11C]2-(4’-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) positron emission tomography (PET) revealed considerable Aβ retention in the bilateral frontal, parietal, and lateral temporal cortices. In addition, severe brain atrophy was detected on the corresponding computed tomography (CT) images, especially in the hippocampi. Bilateral MTA score was 3, indicating severe atrophy of the hippocampus (Fig. 1B). In this FAD pedigree, the proband’s mother (I-1) and one brother (II-2) had had AD.

Fig. 1
figure 1

Family information, PET images, and sequencing chromatogram of a ZDHHC21 mutation in patients with AD. A Family pedigree of the patient with the ZDHHC21 p.T209S mutation. The proband is labeled with an arrow, affected family members with black symbols, and unaffected members with white symbols. Men are denoted with squares, women with circles, and deceased members with slashes through the symbols. B 11C-PIB PET/CT images of the II-6 patient. From left to right: transverse, sagittal, and coronal sections. C The sequencing chromatogram of a heterozygous ZDHHC21 c.999A > T mutation in the patient

Full size image

To identify candidate causal gene variants for this FAD pedigree, we performed exome capture followed by deep sequencing. We did not detect any pathogenic mutations known to cause AD, that is, in the APP, PSEN1, or PSEN2 genes. The APOE genotypes of all family members were shown in Fig. 1A. The AD patients (II-6, I-2) and two non-AD family members (II-1, II-3) had the APOE ε4 allele, but one AD patient (II-2) was APOE ε4 negative. Further, we identified new candidate causative mutations for this family. Two affected members and two asymptomatic control members were selected for exome sequencing. A high level of coverage (> 70 ×) was achieved, with an average of 7.5 × 109 base pairs sequenced per person. The candidate causative variants were identified and filtered, using the following criteria: the variant present in both affected individuals within the family, not present in the unaffected individual within the family, altered the amino acid sequence, and MAF < 0.5%. Remaining variants were filtered for the next step according to the following rules: CADD > 20; GERP +  +  ≤ 4; SIFT < 0.05; PolyPhen-2 > 0.8; MetaLR > 0.5; and M-CAP > 0.025. Finally, a novel, heterozygous, missense mutation (p.T209S) was identified (Fig. 1C). It was confirmed by Sanger sequencing and tested for Mendelian segregation in all affected family members. The mutation was located in exon 6 of the ZDHHC21 gene. This mutation had not previously been reported in either the Genome Aggregation Database (gnomAD), DisGeNET, AD and Frontotemporal Dementia (FTD) Mutation Database [26] or The Human Gene Mutation Database (HGMD [27]). Additionally, the pathogenicity of the mutation was predicted using dbSNP [28] and the Exome Variant Server [29]. Evolutionary conservation analysis revealed that the missense mutation p.T209S resulted in a change of a highly conserved amino acid.

ZDHHC21 mutation induces cognitive decline and aberrant palmitoylation of APP and FYN in mice

We attempted to clarify the pathogenicity biological consequences of the ZDHHC21 p.T209S mutation by generating ZDHHC21T209S/T209S mice with the CRISPR/Cas9 system, substituting adenine with thymine at position 999 in the endogenous Zdhhc21 gene (Additional file 1: Fig. S1). First, to examine the effects of the p.T209S mutation on spatial learning and memory, we let WT and ZDHHC21T209S/T209S mice perform a Morris water navigation task. The groups had comparable swimming speeds, which indicated that they had no significant neuromotor differences. Although all ZDHHC21T209S/T209S mice and their WT littermates managed the task after a 5-day training period, a significantly impaired learning ability was observed in ZDHHC21T209S/T209S mice compared with their WT littermates (Fig. 2A). A probe trial was performed after the last training session to evaluate memory impairment in terms of spatial reference. Decreased memory retention was observed in ZDHHC21T209S/T209S mice compared with their WT littermates (using the number of platform location crosses and time in the target quadrant as readouts) (Fig. 2A). These results demonstrated that the p.T209S mutation induces cognitive impairment in mice.

Fig. 2
figure 2

ZDHHC21 mutation inducing cognitive decline and aberrant palmitoylation of APP and FYN in mice. A The Morris water maze test of WT and ZDHHC21T209S/T209S mice (9 months old), including latency to platform (left), number of platform crosses (middle), and time in the target quadrant (right). B and C Immunoblot showing co-immunoprecipitation of ZDHHC21 with APP (B) or FYN (C) in the WT and p.T209S hippocampi (9 months old). D Immunofluorescence of ZDHHC21, FYN, and DAPI in the WT and p.T209S hippocampi (6 months old). E and F Representative immunoblot (up) and quantification (down) of APP (E) or FYN (F) palmitoylation levels in WT and ZDHHC21T209S/T209S hippocampi (6 months old). G Representative immunoblot (up) and quantification (down) of FYN levels in hippocampal membrane proteins in WT and ZDHHC21.T209S/T209S mice (6 months old). Values are expressed as means ± SEMs of 8 to 11 (A), 3 (B to D), or 4 (E to G) mice per group. Data in B–G were based on three independent experiments. All mouse groups contained mice of both sexes. Data were analyzed via two-way ANOVA with Tukey’s multiple-comparisons test (A: left), unpaired two-tailed Student’s t-tests (A: middle and right, G), and paired two-tailed Student’s t-test (E and F). *P < 0.05, **P < 0.01. Scale bar, 20 μm (D)

Full size image

We examined whether the mutation affected the expression of ZDHHC21; however, neither the mRNA nor protein levels were altered in the ZDHHC21T209S/T209S mouse brain (Additional file 1: Fig. S2A, B). APP and the tyrosine protein kinase FYN were previously reported as potential substrates for palmitoylation by ZDHHC21 [30, 31]. Thus, we determined whether and how palmitoylation of APP and FYN facilitated the pathological process of AD. We discovered an interaction between ZDHHC21 and APP or FYN in both the WT and ZDHHC21T209S/T209S hippocampi (Fig. 2B, C). Colocalization of ZDHHC21 and FYN was identified in both WT and ZDHHC21T209S/T209S hippocampi via double immunofluorescence (Fig. 2D). We attempted to clarify whether the p.T209S mutation affects the enzymatic activity of ZDHHC21 by comparing the palmitoylation of APP and FYN in the hippocampi of WT and ZDHHC21T209S/T209S mice via the acyl-biotin exchange (ABE) assay. The palmitoylation levels of APP and FYN were 47.6% and 25.2% higher, respectively, in the ZDHHC21T209S/T209S hippocampus than those in the WT hippocampus (Fig. 2E, F), while the expression levels of APP and FYN did not differ between the groups (Additional file 1: Fig. S2C, D), indicating that ZDHHC21 p.T209S is a gain-of-function variant causing an increase in enzymatic activity. It was reported that Fyn palmitoylation is important for its localization to the membrane. We assessed the effect of FYN palmitoylation on protein trafficking by investigating whether FYN is enriched in the membranes of ZDHHC21T209S/T209S mice. We isolated membrane proteins from the brain tissue homogenate extracts of WT and ZDHHC21T209S/T209S mice. As expected, FYN was more abundant in the membrane of ZDHHC21T209S/T209S mice than in those of WT mice. Quantitative analysis revealed that FYN level in membrane was 15.5% higher in ZDHHC21T209S/T209S mice than those in WT mice (Fig. 2G).

ZDHHC21 mutation induces Aβ accumulation and tau hyperphosphorylation in mice

Further, we examined the AD-related pathological changes in the hippocampus of ZDHHC21T209S/T209S mice. Widespread, intraneuronal Aβ and p-tau staining was observed in all regions of the hippocampus in ZDHHC21T209S/T209S mice. Similar patterns have been reported in early-stage APP/PS-1 transgenic mice [32] and an APP Sw-NSE mouse model [33]. Measurement of Aβ levels by using an enzyme-linked immunosorbent assay (ELISA) revealed that Aβ40 and Aβ42 species, which are synaptotoxic in AD, were significantly higher (by 53.0% and 129.7%, respectively) in the hippocampus of ZDHHC21T209S/T209S mice than those in WT mice (Fig. 3B); the ratio of Aβ42 to Aβ40 was higher by 56.7% (Fig. 3B). In addition, the phosphorylation level detected by western blotting was higher in ZDHHC21T209S/T209 mice at Thr181, Thr 217, Thr231, and Ser396 in tau (Fig. 3C). Together, these findings demonstrate that the ZDHHC21 p.T209S mutation induces Aβ accumulation and tau hyperphosphorylation in mice.

Fig. 3
figure 3

Mutation of ZDHHC21 inducing AD pathologies in mice. A Representative immunofluorescence images of Aβ and p-tau in the WT and ZDHHC21T209S/T209S hippocampus (9 months old). B Soluble Aβ42 and Aβ40 levels in WT and ZDHHC21T209S/T209S hippocampal tissues (6 months old) were detected using an ELISA. C Representative immunoblot (left) and quantification of tau phosphorylation (right) in WT and ZDHHC21.T209S/T209S hippocampi (6 months old). Values are expressed as means ± SEMs of 3 (A), 9 (B), or 4 (C) mice per group. Data are representative of three independent experiments with similar results. All mouse groups consisted of mice of both sexes. Data were analyzed via unpaired two-tailed Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 200 μm and 100 μm as indicated, respectively (A)

Full size image

ZDHHC21 mutation causes neuronal loss and disturbs synaptic function

We examined hippocampal neuronal apoptosis by using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining along with neuronal markers and neuronal nuclei (NeuN). We discovered that the ZDHHC21 p.T209S mutation induced neuronal apoptosis (Fig. 4A, B). Furthermore, compared with WT mice, the density of functional synapses was markedly lower in the hippocampus of ZDHHC21T209S/T209S mice (Fig. 4C, D). We also detected a significantly lower number of dendritic branches between 60 and 120 mm from the soma in mutant than in WT mice, as measured with Sholl analysis (Fig. 4E, F), as well as a smaller number of dendritic spines (Fig. 4G, H). Lastly, to examine the impact of mutations on synaptic plasticity, we performed field recordings of synaptic long-term potentiation (LTP) induced by one train of high-frequency stimuli in the Schaffer collateral pathway. The magnitudes of the field excitatory postsynaptic potentials (fEPSPs) in ZDHHC21T209S/T209S mice were significantly lower (Fig. 4I, J) than those in WT mice, which was consistent with the observed memory impairment. These results indicate that hippocampal neuronal plasticity is impaired in ZDHHC21T209S/T209S mice.

Fig. 4
figure 4

ZDHHC21 mutation leading to neuronal losses and synaptic dysfunction. A Immunofluorescence analysis of TUNEL-reactive cells in the CA1 regions of WT and ZDHHC21T209S/T209S hippocampi (9 months old). B Quantitative analysis of TUNEL-reactive cells in the CA1 regions of the hippocampus. C Representative set of electron microscopy images of WT and ZDHHC21T209S/T209S hippocampi (9 months old). Synapses are indicated with red arrows. D Quantification of the number of synapses in (C). E Representative Golgi stain image of WT and ZDHHC21T209S/T209S hippocampi (9 months old). F Quantification of the number of dendritic branches per given distance from the soma. G Representative images of Golgi-stained hippocampal pyramidal neurons. H Quantification of the number of dendritic spines in (G). I LTP was induced in acute hippocampal sections from WT and ZDHHC21T209S/T209S mice (3 months old). Exemplary trances in light/dark grey indicate before/after LTP induction for the WT mice, and traces in light/dark red indicate before/after LTP induction for the ZDHHC21T209S/T209S mice. J Quantification of fEPSP–50–60 min after induction. Values are expressed as means ± SEMs of 10 sections from 3 mice per group (B, D), 4 (F) and 3 (H) neurons from 3 mice per group, or 4 to 7 sections from 3 to 5 mice per group (J). Data were analyzed via unpaired two-tailed Student’s t-tests (B, D, F, H and J). ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05. Scale bars, 20 μm (A), 1 μm (C), 50 μm (E: left), 200 μm (E: right), and 10 μm (G)

Full size image

Synaptic dysfunction of ZDHHC21T209S/T209 is mediated via the ZDHHC21-FYN-NMDAR2B pathway

Palmitoylation of proteins affects their subcellular localization and functions [34, 35]. As expected, we observed greater localization of FYN to the cell membrane in the ZDHHC21T209S/T209S hippocampus than in the WT hippocampus (Fig. 2G). FYN was previously reported as a key regulator of N-methyl-d-aspartate receptor (NMDAR) function, which is involved in synaptic plasticity [36]. Subsequently, we assessed the effect of p.T209S on the FYN-NMDAR pathway. The levels of phosphorylated forms of NMDAR subunit epsilon-2 (NMDAR2B) were significantly higher in the ZDHHC21T209S/T209S hippocampus than in the WT hippocampus (Fig. 5A). Excessive NMDAR2B activity can cause excitotoxicity and promote neuronal loss [37]. Upon exposure to 100 μM NMDA, neuronal viability was decreased by 13.8% and 30.0% in WT and p.T209S neurons, respectively (Fig. 5B). These results indicated that p.T209S neurons are more vulnerable to NMDA-mediated excitotoxicity. Thereafter, we investigated whether this increased vulnerability to excitotoxicity resulted from the over-palmitoylation induced by the p.T209S mutation. We treated a subset of neurons with palmitoylation inhibitors (2-bromopalmitate [2-BP] or cerulenin) prior to treatment with NMDA and glycine. Notably, pretreatment with either 2-BP and cerulenin improved the viability of p.T209S neurons similar to that of WT neurons (Fig. 5B). These results indicate that the higher vulnerability of p.T209S neurons to excitotoxicity can be mitigated by correcting palmitoylation.

Fig. 5
figure 5

The effect of the ZDHHC21 mutation on synaptic dysfunction via the FYN-NMDAR2B pathway. A Representative immunoblot (left) and quantification of the phosphorylation of NMDAR2B (right) in WT and ZDHHC21T209S/T209S hippocampi (mean ± s.e.m.; n = 4 mice per group with three independent experiments). B Quantification of cellular viability in DIV18-20 WT and p.T209S neurons treated with NMDA and glycine (100/10 μM) with or without pretreatment with vehicle (dimethyl sulfoxide) only, 2-BP (1 μM), or cerulenin (1 μM) (mean ± s.e.m.; n = 4 mice per group with three independent experiments). C Quantification of the spontaneous calcium transient AUC of WT and p.T209S neurons before and after treatment with Ro25–6981 (mean ± s.e.m.; n = 4 mice per group, 30 synaptic sites in total). D Quantification of the spontaneous calcium transient diffusion distance of WT and p.T209S neurons before and after treatment with Ro25–6981. E Quantification of spontaneous calcium transient AUC in WT, p.T209S, and p.T209S + 2-BP-treated groups. F Quantification of spontaneous calcium transient diffusion distance in WT, p.T209S, and p.T209S + 2-BP-treated groups. Values are expressed as means ± SEMs of 4 mice per group with three independent experiments, 30 synaptic sites in total (C-F). All mouse groups consisted of mice of both sexes. Data were analyzed via one-way ANOVA with Tukey’s post hoc test (B), or unpaired two-tailed Student’s t-tests (A, C, D, E, and F). ***P < 0.001, **P < 0.01, and *P < 0.05

Full size image

Furthermore, NMDAR2B over-activated via phosphorylation maintains an open conformation for a prolonged period of time, allowing increased calcium entry per synaptic event [38]. We directly determined the effects of the ZDHHC21 p.T209S mutation on calcium dynamics by treating WT and p.T209S neurons with Ro 25–6981, a potent and selective inhibitor of NMDAR2B, and performing calcium imaging. At baseline, the area under the curve (AUC) of spontaneous calcium signal (Fig. 5C) and the calcium diffusion distance of synapses in p.T209S neurons were higher than those in WT neurons. After Ro 25–6981 treatment, both the AUC (Fig. 5C) and calcium diffusion distance (Fig. 5D) of synapses in p.T209S neurons were rescued to levels comparable to WT levels, while Ro 25–6981 had virtually no effect on the calcium signals recorded in WT cells. These data revealed that p.T209S neurons had stronger synaptic calcium signaling than WT neurons, which was dependent on NMDAR2B overactivity.

We determined whether palmitoylation inhibitors could affect calcium dynamics in p.T209S neurons by pretreating p.T209S neurons with 2-BP before calcium imaging. Notably, treatment with 2-BP significantly decreased the AUCs of the calcium signal in p.T209S neurons to nearly WT levels (Fig. 5E, Additional file 1: Fig. S3). We observed similar changes in the calcium diffusion distance at synaptic sites (Fig. 5F, Additional file 1: Fig. S3). Our data provide support that chronic palmitoylation inhibitor treatment may correct the abnormal palmitoylation level of FYN, repairing synaptic function.

Discussion

In this study, we encountered a family with eight members in two generations, among which the mother and her one son and one daughter were diagnosed with AD, and we confirmed that Aβ exhibited increased retention in the hippocampal, frontal, and parietal areas. Whole exome sequencing revealed a novel and heterozygous missense mutation (p.T209S) in all family members with AD and in none of the unaffected members, indicating cosegregation. All this clinical information supports the family as an AD pedigree. The mutation is located in exon 6 of ZDHHC21. This missense mutation had not been previously reported according to the AD and FTD Mutation Database. We aimed to clarify whether it is pathological by generating ZDHHC21T209S/T209S mice with the CRISPR/Cas9 system. In this animal model, we observed aberrant palmitoylation of APP and FYN, increased levels of Aβ and phosphorylated tau (p-tau), disturbed synaptic function, neuronal loss, and memory decline (Fig. 6), suggesting that this mutation may be a candidate causal mutation. In terms of the underlying mechanism, the ZDHHC21-FYN-NMDAR2B pathway played a crucial role in these pathological processes. To the best of our knowledge, this is the first report of a pathological gene mutation other than those in PSEN1/PSEN2 and APP in a Chinese FAD pedigree. Importantly, palmitoylation mediated by the ZDHHC21 p.T209S mutation in the development of AD may provide new insights into the pathogenesis of AD.

Fig. 6
figure 6

Proposed role of aberrant palmitoylation mediated via ZDHHC21 p.T209S in the development of AD. The ZDHHC21 p.T209S mutation improves enzymatic activity, affects the palmitoylation of APP and FYN, subsequently contributes to the aggravation of the Aβ pathology and synaptic dysfunction, and finally causes cognitive impairment and other AD-related symptoms

Full size image

In our study, the ZDHHC21 p.T209S mutation enhanced palmitoylation of APP in the hippocampus. Protein palmitoylation plays vital roles in regulating protein stability, subcellular localization, membrane trafficking, and various other cellular processes [30, 39, 40]. Overexpression of ZDHHC21 reportedly increases palmitoylation of APP in PC-12 cells [41]. APP can be processed by BACE1 and γ-secretase, which are both found in membrane microdomains known as detergent-resistant lipid rafts [42, 43]. Palmitoylated APP (palAPP) is preferentially targeted to lipid rafts, where palAPP serves as a better substrate for BACE1 cleavage for Aβ generation than does unmodified APP in vivo [31]. Usually, 10% of APP proteins undergoes post-translational palmitoylation. In the current study, we discovered that the p.T209S mutation enhanced APP palmitoylation, followed by an increase in Aβ40 and Aβ42 levels in the hippocampus of ZDHHC21T209S/T209S mice. Aβ generation has traditionally been thought to involve continuous cleavage of β- and γ-secretase [44, 45]. Accordingly, mutations in PSEN1, PSEN2, and APP, identified in FAD, were reported to increase Aβ production by regulating the catalytic activity and/or aberrant expression of proteins [46]. The proteolytic events resulting in Aβ production are well characterized [47], but do not explain the mechanism in pedigrees without PSEN1/PSEN2 or APP mutations. In our study, ZDHHC21 p.T209S, the first probable pathological mutation identified in a Chinese FAD pedigree (apart from those in PSEN1/PSEN 2 and APP), caused an increase in Aβ accumulation in the mouse brain by enhancing the palmitoylation of APP, which occurred before β- and γ-secretase cleavage of APP. This indicates that the modification of APP, which led to an increase in Aβ production in the present study, was different from the mechanism previously reported in FAD.

In this study, FYN hyperpalmitoylation was identified in ZDHHC21T209S/T209S mice, implying that this mutation disturbed the palmitoylation activity of ZDHHC21. FYN is a direct palmitoylation target of ZDHHC21, and its palmitoylation determines its localization and function in multiple signaling pathways [48]. A previous study demonstrated that mutation of the depalmitoylating enzyme palmitoyl-protein thioesterase 1 (PPT1) causes FYN hyperpalmitoylation, which impairs synaptic transmission and plasticity [25, 49]. Our results also revealed that FYN hyperpalmitoylation induced by the p.T209S mutation reduced the number of synapses and impaired synaptic plasticity. NMDAR2B was previously reported as a major target of FYN [50, 51]. FYN phosphorylates NMDAR2B, increasing NMDAR2B trafficking and membrane stabilization, which results in abnormal synaptic transmission and plasticity [52,53,54]. Overactivation of NMDARs causes excitotoxicity and neuronal cell damage, and chronic NMDAR hyperactivity contributes to neuronal loss in the development of AD [37, 55] We demonstrated that hyperpalmitoylated FYN increases NMDAR phosphorylation, resulting in ZDHHC21T209S/T209S neurons being more susceptible to NMDA-induced excitotoxicity of postsynaptic receptors, similar to that reported in Ppt1−/− neurons [25]. In addition, an age-related increase in palmitoylated FYN in the frontal cortex is reportedly associated with poorer reference memory and/or executive functions, suggesting that a perturbation in palmitoylation may contribute to age-related cognitive decline [56]. We also observed that learning and memory were seriously impaired in ZDHHC21T209S/T209S mice, suggesting that activation of FYN signaling induced by the ZDHHC21 mutation was closely associated with cognitive decline.

It would be interesting to determine whether ZDHHC21 is a useful target in AD therapeutics, as elevated levels of palmitoylation seem to have a detrimental role in synaptic integrity and function in AD. Notably, in this study, the chronic palmitoylation inhibitors 2-BP and cerulenin mitigated the increased sensitivity and the impaired synaptic function of ZDHHC21T209S/T209S neurons, which suggested that maintenance of a palmitoylation balance may be used as therapeutic strategy for AD. In the future, animal experiments should be conducted to explore the therapeutic effects of palmitoylation inhibitors on AD mice.

In the present study, a novel, heterozygous missense mutation (ZDHHC21 p.T209S) was detected by whole exome sequencing in an FAD pedigree. This mutation was detected in all family members with AD, while it was not present in unaffected members, indicating cosegregation and a possible pathogenicity. To clarify the pathogenicity of ZDHHC21 T209S mutation in AD, ZDHHC21T209S/T209S mice were generated. This model showed reduced spatial learning function, impaired synaptic function, and increased Aβ production and tau phosphorylation. This mouse model may not completely replicate the pathology of AD in humans because of the absence of Aβ plaques. In existing AD mouse models, mice with only PSEN or MAPT gene mutations did not produce Aβ plaques; the same was true for mice with single APP mutations, such as APP E693Δ-Tg, APP Dutch, and APP Sw-NSE [33, 57, 58]. Based on the analysis of AD mouse models and the findings of this study, we suspect that human APP and multiple mutations may facilitate the development of Aβ plaques; however, this requires more exploration. Although the ZDHHC21 T209S mutation was identified in a Chinese FAD pedigree, its relevance to AD morbidity in the population should be further studied in the future.

Conclusions

In conclusion, we have provided multiple lines of supporting evidence that the ZDHHC21 p.T209S mutation contributes to AD by enhancing the palmitoylation of APP and FYN, impairing the synapses, and aggravating Aβ pathology, tau hyperphosphorylation, and neuronal loss, ultimately causing cognitive impairment in mice. Our results indicate that modified palmitoylation of ZDHHC21-specific substrates is an alternative mechanism driving AD and a potential target for drug therapy.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Abbreviations

AD:

Alzheimer’s disease

ABE:

Acyl-biotin exchange

Aβ:

Amyloid beta

APP:

Aβ precursor protein

AUC:

Area under the curve

2-BP:

2-Bromopalmitate

CFAN:

Chinese Familial Alzheimer’s Disease Network

CDR:

Clinical Dementia Rating

11C-PIB:

N-methyl-[11C]2-(4’-methylaminophenyl)-6-hydroxybenzothiazole

CT:

Computed tomography

ELISA:

Enzyme-linked immunosorbent assay

FAD:

Familial Alzheimer’s disease

fEPSPs:

Field excitatory postsynaptic potentials

FTD:

Frontotemporal Dementia

LTP:

Long-term potentiation

MMSE:

Mini-Mental State Examination

NeuN:

Neuronal nuclei (NeuN)

NMDAR:

N-methyl-d-aspartate receptor

NMDAR2B:

NMDAR subunit epsilon-2

PET:

Positron emission tomography

PPT1:

Palmitoyl-protein thioesterase 1

PSEN1:

Presenilin-1

PSEN:

Presenilin-2

p-tau:

Phosphorylated tau

TUNEL:

Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling

ZDHHC21:

Zinc finger DHHC-type palmitoyltransferase 21

References

  1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118(1):5–36.

    Article  CAS  PubMed  Google Scholar 

  2. Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, et al. Brain atrophy in Alzheimer’s Disease and aging. Ageing Res Rev. 2016;30:25–48.

    Article  PubMed  Google Scholar 

  3. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–8.

    Article  PubMed  Google Scholar 

  5. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375(6534):754–60.

    Article  CAS  PubMed  Google Scholar 

  6. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature. 1995;376(6543):775–8.

    Article  CAS  PubMed  Google Scholar 

  7. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349(6311):704–6.

    Article  CAS  PubMed  Google Scholar 

  8. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science. 1995;269(5226):973–7.

    Article  CAS  PubMed  Google Scholar 

  9. van Duijn CM, Hendriks L, Cruts M, Hardy JA, Hofman A, Van Broeckhoven C. Amyloid precursor protein gene mutation in early-onset Alzheimer’s disease. Lancet. 1991;337(8747):978.

    Article  PubMed  Google Scholar 

  10. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7(1):43–51.

    Article  CAS  PubMed  Google Scholar 

  11. Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer’s disease. Alzheimers Dement. 2020;16(1):178–91.

    Article  PubMed  Google Scholar 

  12. Jutten RJ, Sikkes SAM, Van der Flier WM, Scheltens P, Visser PJ, Tijms BM, et al. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology. 2021;96(22):e2673–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740–54.

    Article  CAS  PubMed  Google Scholar 

  14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jarvik GP, Browning BL. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. Am J Hum Genet. 2016;98(6):1077–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang Y, Cheng Z, Qin W, Jia J. Val97Leu mutant presenilin-1 induces tau hyperphosphorylation and spatial memory deficit in mice and the underlying mechanisms. J Neurochem. 2012;121(1):135–45.

    Article  CAS  PubMed  Google Scholar 

  18. Pang Y, Li T, Wang Q, Qin W, Li Y, Wei Y, et al. A Rare Variation in the 3’ Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer’s Disease. Mol Neurobiol. 2021;58(9):4337–47.

    Article  CAS  PubMed  Google Scholar 

  19. Li W, Wang S, Zhang H, Li B, Xu L, Li Y, et al. Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming. J Alzheimers Dis. 2021;82(4):1475–85.

    Article  CAS  PubMed  Google Scholar 

  20. Jensen EC. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken). 2013;296(3):378–81.

    Article  PubMed  Google Scholar 

  21. Yang W, Di Vizio D, Kirchner M, Steen H, Freeman MR. Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol Cell Proteomics. 2010;9(1):54–70.

    Article  CAS  PubMed  Google Scholar 

  22. Bird AD, Cuntz H. Dissecting Sholl Analysis into Its Functional Components. Cell Rep. 2019;27(10):3081-96 e5.

    Article  CAS  PubMed  Google Scholar 

  23. Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 2014;20(11):1254–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.

    Article  CAS  PubMed  Google Scholar 

  25. Koster KP, Francesconi W, Berton F, Alahmadi S, Srinivas R, Yoshii A. Developmental NMDA receptor dysregulation in the infantile neuronal ceroid lipofuscinosis mouse model. Elife. 2019;8:e40316.

  26. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012;33(9):1340–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. dbSNP. https://www.ncbi.nlm.nih.gov/snp/. 6 January 2021.

  29. Exome Variant Server. https://evs.gs.washington.edu/EVS/. 23 April 2019.

  30. Jin J, Zhi X, Wang X, Meng D. Protein palmitoylation and its pathophysiological relevance. J Cell Physiol. 2021;236(5):3220–33.

    Article  CAS  PubMed  Google Scholar 

  31. Bhattacharyya R, Barren C, Kovacs DM. Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J Neurosci. 2013;33(27):11169–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, et al. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002;12(3):275–86.

    Article  CAS  PubMed  Google Scholar 

  33. Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, et al. Aberrant expressions of pathogenic phenotype in Alzheimer’s diseased transgenic mice carrying NSE-controlled APPsw. Exp Neurol. 2004;186(1):20–32.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang Z, Li X, Yang F, Chen C, Liu P, Ren Y, et al. DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis. Nat Commun. 2021;12(1):5872.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Chamberlain LH, Shipston MJ. The physiology of protein S-acylation. Physiol Rev. 2015;95(2):341–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rajani V, Sengar AS, Salter MW. Src and Fyn regulation of NMDA receptors in health and disease. Neuropharmacology. 2021;193: 108615.

    Article  CAS  PubMed  Google Scholar 

  37. Weilinger NL, Lohman AW, Rakai BD, Ma EM, Bialecki J, Maslieieva V, et al. Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity. Nat Neurosci. 2016;19(3):432–42.

    Article  CAS  PubMed  Google Scholar 

  38. Hubalkova P, Ladislav M, Vyklicky V, Smejkalova T, Hrcka Krausova B, Kysilov B, et al. Palmitoylation Controls NMDA Receptor Function and Steroid Sensitivity. J Neurosci. 2021;41(10):2119–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Fukata Y, Fukata M. Protein palmitoylation in neuronal development and synaptic plasticity. Nat Rev Neurosci. 2010;11(3):161–75.

    Article  CAS  PubMed  Google Scholar 

  40. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol. 2007;8(1):74–84.

    Article  CAS  PubMed  Google Scholar 

  41. Bhattacharyya R, Fenn RH, Barren C, Tanzi RE, Kovacs DM. Palmitoylated APP Forms Dimers, Cleaved by BACE1. PLoS ONE. 2016;11(11):e0166400.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Zhang X, Song W. The role of APP and BACE1 trafficking in APP processing and amyloid-beta generation. Alzheimers Res Ther. 2013;5(5):46.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Bera S, Camblor-Perujo S, Calleja Barca E, Negrete-Hurtado A, Racho J, De Bruyckere E, et al. AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons. EMBO Rep. 2020;21(6):e47954.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1:15056.

    Article  PubMed  Google Scholar 

  45. Guo Q, Wang Z, Li H, Wiese M, Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012;22(1):78–89.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang S, Zhang M, Cai F, Song W. Biological function of Presenilin and its role in AD pathogenesis. Transl Neurodegener. 2013;2(1):15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5): a006270.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mill P, Lee AW, Fukata Y, Tsutsumi R, Fukata M, Keighren M, et al. Palmitoylation regulates epidermal homeostasis and hair follicle differentiation. PLoS Genet. 2009;5(11):e1000748.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15(9):1227–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Trepanier CH, Jackson MF, MacDonald JF. Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J. 2012;279(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  51. Nygaard HB. Targeting Fyn Kinase in Alzheimer’s Disease. Biol Psychiatry. 2018;83(4):369–76.

    Article  CAS  PubMed  Google Scholar 

  52. Xia D, Gotz J. Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. Front Mol Neurosci. 2014;7:40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2001;276(1):693–9.

    Article  CAS  PubMed  Google Scholar 

  54. Tezuka T, Umemori H, Akiyama T, Nakanishi S, Yamamoto T. PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc Natl Acad Sci U S A. 1999;96(2):435–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013;4:e560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Zamzow DR, Elias V, Acosta VA, Escobedo E, Magnusson KR. Higher Levels of Protein Palmitoylation in the Frontal Cortex across Aging Were Associated with Reference Memory and Executive Function Declines. eNeuro. 2019;6(1):0310–18.

  57. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30(14):4845–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7(9):954–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Meina Quan for discussion and analysis of CT image data.

Funding

This study was supported by the Key Project of the National Natural Science Foundation of China (U20A20354); Beijing Brain Initiative from Beijing Municipal Science & Technology Commission (Z201100005520016, Z201100005520017); National major R&D projects of China-Scientific technological innovation 2030 (2021ZD0201802); the National Key Scientific Instrument and Equipment Development Project (31627803); the Key Project of the National Natural Science Foundation of China (81530036).

Author information

Author notes

  1. Wenwen Li, Yana Pang and Yan Wang contributed equally.

Authors and Affiliations

  1. Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China

    Wenwen Li, Yana Pang, Yan Wang, Mengmeng Guo, Yiping Wei, Xinyue Li, Wei Qin, Wei Wang, Longfei Jia & Jianping Jia

  2. Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

    Fan Mei

  3. Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China

    Jianping Jia

  4. Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China

    Jianping Jia

  5. Center of Alzheimer’s Disease, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China

    Jianping Jia

  6. Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China

    Jianping Jia

Authors
  1. Wenwen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yana Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fan Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mengmeng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yiping Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xinyue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Longfei Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jianping Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.J. and W.L. designed and coordinated the study and wrote the manuscript. W.L., Y.P. and Y.W. carried out most studies and data analysis. J.J., W.Q. and W.W. found the FAD pedigree. L.J. designed and conducted the mouse model. Y.W. and M.G. managed mouse lines and contributed to brain collections. X.L. conducted immunohistochemical studies. F.M. performed electrophysiology experiment. J.J. supervised the project. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jianping Jia.

Ethics declarations

Ethics approval and consent to participate

The institutional review board of Xuanwu Hospital, Capital Medical University, approved this study ([2019]110), and all participants provided written informed consent.

All experimental animal procedures were approved by the Ethics Committee of Capital Medical University (2010-X-098).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

12916_2023_2930_MOESM1_ESM.pdf

Additional file 1: Fig S1.Construction of ZDHHC21T209S/T209S mice. Fig S2. The expression of ZDHHC21, APPand FYNin WT and ZDHHC21T209S/T209S mice. Fig S3. Representative tracesat one synaptic site fromWT, T209Sand T209S+2-BPneurons.

12916_2023_2930_MOESM2_ESM.pdf

Additional file 2: Figure S1.The original blot images of ZDHHC21 and APP in Figure 2B. Figure S2. The original blot images of ZDHHC21 and FYN in Figure2C. Figure S3. The original blotimages of APP in Figure 2E. Figure S4.The original blot images of FYN in Figure 2F. Figure S5. The original blot images of FYN and E-cadherin in Figure2G. Figure S6. The original blotimages of P-tau, P-tau, P-tau, T-tau and Actin in Figure 3C. Figure S7. The original blot images ofP-NMDAR2B, NMDAR2B and E-cadherin in Figure 5A.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W., Pang, Y., Wang, Y. et al. Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer’s disease. BMC Med 21, 223 (2023). https://doi.org/10.1186/s12916-023-02930-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12916-023-02930-7

Keywords

BMC Medicine

ISSN: 1741-7015

Contact us